Change - Announcement of Appointment::Re-designation to Executive Vice Chairman

Issuer & Securities

Issuer/ Manager
HEALTHWAY MEDICAL CORPORATION LIMITED
Securities
HEALTHWAY MEDICAL CORP LTD - SG1X09940682 - 5NG
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Appointment
Date &Time of Broadcast
07-Mar-2023 17:58:37
Status
New
Announcement Sub Title
Re-designation to Executive Vice Chairman
Announcement Reference
SG230307OTHRFAGV
Submitted By (Co./ Ind. Name)
Chew Pei Tsing
Designation
Secretary
Description (Please provide a detailed description of the event in the box below)
Re-designation of Executive Director and Deputy CEO to Executive Vice Chairman

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assume no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Foo Jien Jieng, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.

Additional Details

Date Of Appointment
09/03/2023
Name Of Person
Abram Melkyzedeck Suhardiman
Age
34
Country Of Principal Residence
Singapore
The Board's comments on this appointment (including rationale, selection criteria, board diversity considerations, and the search and nomination process)
The Board of Directors, after considering the recommendation of the Nominating Committee and having reviewed and considered the qualifications, work experience and performance (including his nearly four years as Executive Director of the Company), and suitability of Mr Abram Melkyzedeck Suhardiman, is of the view that Mr Suhardiman possesses the requisite experience and capabilities to assume the responsibilities of the Executive Vice Chairman of the Company and its subsidiaries ("Group") and that he will continue to contribute positively to the Group.

Accordingly, and in line with the Group's succession planning, the Board of Directors approved the re-designation of Mr Suhardiman from his existing role of Executive Director and Deputy Chief Executive Officer to the position of Executive Vice Chairman.
Whether appointment is executive, and if so, the area of responsibility
The appointment is executive. Mr. Suhardiman will be responsible for the Group's overall growth strategy and corporate development.
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Executive Vice Chairman
Professional qualifications
Master's Program in Finance, Hult International Business School, San Francisco, CA, USA, 2012

Bachelor of Science in Business Administration, University of Southern California, Los Angeles, CA, USA, 2010
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/ or substantial shareholder of the listed issuer or any of its principal subsidiaries
Son-in-law of Dr Stephen Riady, a Non-Independent Non-Executive Director of the Company
Conflict of interests (including any competing business)
Nil
Working experience and occupation(s) during the past 10 years
2020 to Present
Deputy Chief Executive Officer of the Company

2019 to Present
Executive Director of the Company

2017 to 2020
Chief Operating Officer of the Company

2015 to 2017
Vice President, Business Development & Investor Relations, Nuvest Capital

2013 to 2015
Analyst, The Abraaj Group

2012 to 2013
Business Development Manager, PT Artha Cipta Langgeng
Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6))
Yes
Shareholding interest in the listed issuer and its subsidiaries?
Yes
Shareholding Details
Mr Suhardiman holds a total of 68,918,900 ordinary shares in the share capital of the Company in his own name.
Other Principal Commitments* Including Directorships#
*"Principal Commitments" has the same meaning as defined in the Code
# These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8).
Past (for the last 5 years)
Nuvest Real Return Fund
Present
Directorships

1) City Ocean Group Limited
2) TIH Limited
3) MoolahGo Pte. Ltd.
4) IPP Financial Services Holdings Limited
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?
No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?
No
(c) Whether there is any unsatisfied judgment against him?
No
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?
No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?
No
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?
No
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?
No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?
No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?
No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or
No
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or
No
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or
No
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?
Yes
If Yes, Please provide full details
Mr Abram Melkyzedeck Suhardiman has been an Executive Director of Healthway Medical Corporation (the "Company") since 26 April 2019.

The Company had received enquiries and communicated with the Singapore Exchange Regulation Pte. Ltd. in relation to its obligations under Catalist Listing Rule 703(4)(a) read with paragraph 27(a) of the Corporate Disclosure Policy. This arose from certain inaccurate disclosures in the Company's annual report for the financial year ended 31 December 2019 ("AR 2019") pertaining to the re-election of Mr Sin Boon Ann and the appointment of Ms Poh Mui Hoon.

The AR 2019 had been announced on the SGXNet on 15 April 2020 and the aforesaid disclosures were subsequently revised and corrected by way of a corrigendum to the AR 2019 announced on the SGXNet on 22 June 2020.
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?
No
Disclosure applicable to the appointment of Director only.
Any prior experience as a director of an issuer listed on the Exchange?
Yes
If Yes, Please provide details of prior experience
Mr Suhardiman is an Executive Director and, prior to his re-designation to the position of Executive Vice Chairman, is a Deputy Chief Executive of the Company. He is also an Alternate Director on the Board of TIH Limited since 2020, a company listed on the Main Board of SGX-ST.
Please provide details of relevant experience and the nominating committee's reasons for not requiring the director to undergo training as prescribed by the Exchange (if applicable)
N.A.